Table 3.
Median (95% CI) OS (months) – CALGB 80303, 40503, 80405 – and 75th percentile (95% CI) OS (months) – ICON7 – for rs680949 in PRUNE2 (A>G, MAF 0.06–0.07) and rs16852804 in BARD1 (G>A, MAF 0.06–0.10), prognostic effect, and for rs3795897 in AGAP1 (G>A, MAF 0.11–0.17), predictive effect.
| Prognostic effect: rs680949 in PRUNE2 (A>G, MAF 0.06–0.07) | ||||||||
|
| ||||||||
| Genotype |
CALGB 80303
Median OS (95% CI) - n |
CALGB 40503
Median OS (95% CI) - n |
CALGB 80405
Median OS (95% CI) - n |
ICON7 75th percentile OS (95% CI) - n |
||||
|
| ||||||||
| AA | 6.4 (5.7–7.2) - 253 | 48.7 (42.2–51.3) - 183 | 31.1 (28.1–34.5) −527 | 33.1 (29.9–41.1) - 360 | ||||
| AG | 4.9 (3.7–6.9) - 40 | 36.3 (24.5- NE) – 21 | 18.8 (12.9–27.6) - 81 | 23.9 (17.1–29.2) - 50 | ||||
| GG | 12.0 (NE-NE) - 1 | 16.3 (NE-NE) - 1 | 32.2 (19.8-NE) – 2 | NR (NE-NE) - 1 | ||||
|
| ||||||||
| Prognostic effect: rs16852804 in BARD1 (G>A, MAF 0.06–0.10) | ||||||||
|
| ||||||||
| Genotype |
CALGB 80303
Median OS (95% CI) - n |
CALGB 40503
Median OS (95% CI) - n |
CALGB 80405
Median OS (95% CI) - n |
ICON7 75th percentile OS (95% CI) - n |
||||
|
| ||||||||
| GG | 6.5 (5.8–7.2) - 263 | 48.7 (40.4–51.3) - 168 | 29.6 (26.7–33.0) - 537 | 32.3 (27.6–38.9) - 362 | ||||
| GA | 3.8 (2.7–6.8) - 29 | 42.2 (35.0-NE) - 35 | 29.0 (19.3–36.4) - 70 | 38.8 (22.9-NE) - 45 | ||||
| AA | 13.9 (0.4-NE) - 2 | 39.9 (17.9-NE) - 2 | 15.9 (6.11-NE) - 2 | NR (11.1-NE) - 4 | ||||
|
| ||||||||
| Predictive effect: rs3795897 in AGAP1 (G>A, MAF 0.11–0.17) | ||||||||
|
| ||||||||
|
CALGB 80303
Median OS (95% CI) - n |
CALGB 40503
Median OS (95% CI) - n |
CALGB 80405*
Median OS (95% CI) - n |
ICON7 75th percentile OS (95% CI) - n |
|||||
|
| ||||||||
| Genotype | Placebo | Bevacizumab | Placebo | Bevacizumab | Cetuximab | Bevacizumab | No bevacizumab | Bevacizumab |
|
| ||||||||
| GG | 6.31 (5.22–7.88) −107 | 6.54 (4.90–7.33) - 118 | 46.6 (36.4-NE) −75 | 49.2 (40.4-NE)- 87 | 23.2 (18.7–28.8) - 66 | 31.7 (25.2–41.0) - 71 | 27.6 (24.0-NE) - 160 | 37.0 (33.1-NE) −157 |
| GA | 5.45 (3.78–9.66) - 30 | 5.06 (3.71–6.64) - 33 | 40.1 (35.8-NE) - 22 | 33.4 (22.2-NE) −16 | 41.1 (22.5–60.9) - 35 | 30.1 (11.2–39.7) −20 | NR (1.91-NE) - 36 | 26.1 (21.1-NE) - 49 |
| AA | 6.08 (4.99–7.88) - 3 | 7.23 (2.83-NE) - 3 | NR (35.5-NE) - 2 | NR (22.7-NE) −2 | 45.9 (45.9-NE) - 4 | 22.0 (NE-NE) - 3 | NR (NE-NE) - 3 | 17.4 (16.3-NE) - 6 |
*
genotyped only in patients from the GWAS-Batch 1 (n=199, Fig. S1). CALGB Cancer and Leukemia Group B, ICON7 International Collaboration on Ovarian Neoplasms; OS overall survival; CI confidence interval; NR not reached; NE not estimated.